teplizumab
Sign in to saveTeplizumab, sold under the brand name Tzield among others, is an anti-CD3 humanized monoclonal antibody that is the first approved treatment indicated to delay the onset of stage 3 type1 diabetes in people with stage 2 type1 diabetes.
In the Vinony graph
Within Vinony's link graph, teplizumab is referenced by 262 other articles, and connects out to humanized antibody, monoclonal antibody and fusion protein.
It sits within the topics Anti-diabetic drugs, Chemicals that do not have a ChemSpider ID assigned and Drugs that are a monoclonal antibody.
Its subject is documented across 12 Wikipedia language editions.
Key facts
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- zu/o
- Drug.target
- CD3
- Drug.tradename
- Tzield, others
- Drug.MedlinePlus
- a622077
- Drug.DailyMedID
- Teplizumab
- Drug.routes_of_administration
- Intravenous
- Drug.class
- Antidiabetic agent
- Drug.ATC_prefix
- A10
- Drug.ATC_suffix
- XX01
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- /Schedule D
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 876387-05-2
- Drug.DrugBank
- DB06606
- Drug.ChemSpiderID
- none
via Wikipedia infobox
Wikidata facts
- Subclass of
- chemical compound
Show 2 more facts
- subject has role
- monoclonal antibody
- World Health Organisation international non-proprietary name
- téplizumab
via Wikidata · CC0
~4 min read
Encyclopedic overview
6 sectionsContents
- Medical uses
- History
- Society and culture
- Legal status
- Research
- References
Teplizumab, sold under the brand name Tzield among others, is an anti-CD3 humanized monoclonal antibody that is the first approved treatment indicated to delay the onset of stage 3 type1 diabetes in people with stage 2 type1 diabetes.
Teplizumab's mechanism of action involves binding to CD3 protein complexes (a molecule involved in recognising antigens and activating T cells) on the surface of T-cells and modifying T-cell immune behaviour to reduce cytotoxicity. This appears to involve weak agonistic activity on signaling via the T cell receptor-CD3 complex associated with the development of anergy, unresponsiveness, and/or apoptosis, particularly of unwanted activated T effector cells. In addition, regulatory cytokines are released and regulatory T cells are expanded that may lead to the reestablishment of immune tolerance. To avoid overly stimulating cytokine release, the Fc region of this antibody has been engineered to have Fc receptor non-binding (FNB) properties.
Excerpted from Wikipedia’s “teplizumab” article, available under the CC BY-SA 4.0 licence.